Innovations in Cardioprotective Pharmacology: Targeting Key Pathways in Myocardial Infarction

Myocardial infarction (MI) remains a significant cause of death globally, with few therapeutic agents available to prevent infarction effectively and promote cardiac recovery. Despite the advancement of reperfusion therapy, adverse myocardial remodeling and reperfusion injury continue to dominate complications, and novel cardioprotective agents are needed to target important molecular pathways. This review examined recent advances in cardioprotective agents, focusing on their molecular mechanisms of action and their potential to prevent myocardial infarction (MI) and promote cardiac recovery. An extensive literature review was conducted, covering emerging pharmacological agents as well as evidence from preclinical and clinical trials. Key areas of interest include agents that modulate inflammation, cell death, metabolic reprogramming, and repair processes. The review integrates pharmacology, molecular medicine, and clinical cardiology evidence to provide a broader research perspective. Novel cardioprotective agents, including flavonoids that regulate miRNA, cardiac myosin-targeted inhibitors, apelin analogs, and cell-free nanotherapies, were identified. Agents act on critical molecular pathways, including oxidative stress, apoptosis, and glucose metabolism, to reduce infarct size and facilitate myocardial recovery. Conventional drugs such as Shaosha-7 have also yielded new findings in MI treatment through sucrose metabolism regulation. New cardioprotective agents promise to reduce MI-induced damage and facilitate long-term recovery. Targeting molecular pathways like inflammation, cell survival, and metabolism is a new trend in MI treatment. Clinical trials and further research are necessary to assess these agents’ long-term benefits and application in the clinic.